Cardlytics, Inc. (CDLX) — Insider Trading

AI-Powered SEC Filing Analysis

Latest Insider Trading Filed: 2026-04-06

Key Insights

Insider Amit Gupta, the Chief Executive Officer, sold 69,833 shares of Cardlytics, Inc. (CDLX) stock on April 6, 2026 to satisfy tax withholding obligations from the vesting of RSUs.
The shares were sold at a weighted average price of $1.187, which is within the reported range of $1.135 to $1.230 per share.
Gupta continues to beneficially own 987,387 shares of Cardlytics stock following the reported sale.

Want the newest filings?

This analysis covers the filing from 2026-04-06. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Insider Trading filings

Filed: 2026-03-03

Amit Gupta, the CEO of Cardlytics, Inc. (CDLX), has been granted a substantial award of 1,500,000 restricted stock units (RSUs), indicating the company's commitment to retaining its key executive.
The RSUs will vest over a two-year period, aligning Gupta's interests with those of Cardlytics' shareholders and providing an incentive for him to continue driving the company's success.
The large size of the RSU award, representing a significant portion of Gupta's overall equity stake, suggests the board's confidence in his leadership and the company's future growth prospects.

Filed: 2026-02-20

The reporting person, Nicholas Lynton Hollmeyer, was granted 220,000 restricted stock units (RSUs) as the Chief Legal & Privacy Officer of Cardlytics, Inc.
The RSUs will vest in equal amounts quarterly over a two-year period through April 1, 2028, provided that the reporting person remains employed by the company.
This RSU grant represents a long-term incentive and alignment of the reporting person's interests with those of the company and its shareholders.

Filed: 2026-01-16

David Thomas Evans, the Chief Financial Officer of Cardlytics, Inc., received 1,000,000 restricted stock units (RSUs) on January 12, 2026, which will vest over a two-year period.
The RSU grant represents a significant equity award for the CFO, signaling the company's commitment to retaining key leadership.
The vesting schedule, with 50% vesting in the first year and the remaining 50% vesting over the next year, suggests a focus on long-term alignment between the CFO and shareholders.

Other reports for Cardlytics, Inc.

Current Report Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.